Biosimilar Application Reviews May Be Growing More Challenging
Executive Summary
FDA assigns more staff to work on the four biosimilar applications that arrived after Zarxio, suggesting those reviews have been tougher.
You may also be interested in...
Biosimilar User Fee Negotiations Won't Start Until 2016
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared
How agency handled issues around protein content differences, statistical analyses of quality data and immunogenicity testing for Sandoz’s Zarxio may prove instructive for future 351(k) applicants.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.